Cumberland Pharmaceuticals (CPIX, Financial) experienced a notable stock price increase of 5.66%. The stock is currently priced at $1.12 per share, with a trading volume of 18,552 shares, a turnover rate of 0.13%, and a price fluctuation of 4.72%.
Recent financial reports reveal that Cumberland Pharmaceuticals generated $9.09 million in revenue, with a net loss of $1.54 million, resulting in an earnings per share (EPS) of -$0.11 and a gross profit of $6.65 million. The price-to-earnings (P/E) ratio stands at -1.46. Currently, no institutional ratings are available for this stock, indicating no buy, hold, or sell recommendations.
Within the pharmaceutical sector, the overall increase was 2.17%. Notable performers include Biofrontera Inc, Procaps Group S.A., and Sunshine Biopharma Inc. Sunshine Biopharma Inc, Painreform Ltd., and Biofrontera Inc showed high activity with turnover rates of 64.13%, 39.92%, and 12.32%, respectively. Stocks with significant price fluctuations include Procaps Group S.A., Sunshine Biopharma Inc, and Akanda Corp, with amplitudes of 35.45%, 29.51%, and 23.87%.
Cumberland Pharmaceuticals is a specialty pharmaceutical company focused on acquiring, developing, and commercializing branded prescription products. The company targets key markets such as hospital acute care, gastroenterology, rheumatology, and oncology. It promotes its approved products through its U.S. hospital, field, and oncology sales divisions while establishing an international partner network to register and provide medicines to patients globally. Revenue is primarily derived from the sales of FDA-approved drug brands, including Acetadote, Caldolor, Kristalose, Omeclamox, Sancuso, Vaprisol, and Vibativ.
